Low Dose Pregabalin Improves Gastrointestinal Symptoms of Crohn's Disease.


Journal

Case reports in gastrointestinal medicine
ISSN: 2090-6528
Titre abrégé: Case Rep Gastrointest Med
Pays: United States
ID NLM: 101580185

Informations de publication

Date de publication:
2024
Historique:
received: 23 10 2023
revised: 28 01 2024
accepted: 22 02 2024
medline: 25 3 2024
pubmed: 25 3 2024
entrez: 25 3 2024
Statut: epublish

Résumé

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are lifelong conditions with no definite cure. Several studies demonstrated that patients with IBD more frequently experience symptoms of common mental disorders, such as anxiety and depression, because of bidirectional communication through the gut-brain axis and the chronicity of symptoms, as well as because of impaired quality of life and reduced social functioning. However, psychological conditions of affected patients are often underestimated and not fully considered. Herein, we present the case of a 37-year-old woman with Crohn's disease and a mild depressive condition, characterized by anxious distress, tachycardia, tachypnea, tremors, sweating, avoidant behaviors, and intestinal somatizations (diarrhea), who was treated with Pregabalin upon indication of the referring psychiatrist. Following the beginning of the treatment, the patient rapidly reported an improvement in the overall clinical symptoms as well as a better management of psychic and physical anxiety with a marked reduction in diarrheal discharges under stress at work. After 6 months of Pregabalin therapy, we additionally observed an improvement in Crohn's disease activity, both clinically, in the laboratory, and endoscopically. Our case showed that patients with Crohn's disease and anxiety problems may benefit from low-dose Pregabalin medication to improve both their mental and physical condition.

Identifiants

pubmed: 38524665
doi: 10.1155/2024/3744500
pmc: PMC10959577
doi:

Types de publication

Case Reports

Langues

eng

Pagination

3744500

Informations de copyright

Copyright © 2024 Antonio Maria D'Onofrio et al.

Déclaration de conflit d'intérêts

The authors declare that there are no conflicts of interest regarding the publication of this article.

Auteurs

Antonio Maria D'Onofrio (AM)

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Rome 00168, Italy.

Federica Di Vincenzo (F)

UOS Malattie Infiammatorie Croniche Intestinali, CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy.

Gaspare Filippo Ferrajoli (GF)

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Rome 00168, Italy.

Franco Scaldaferri (F)

UOS Malattie Infiammatorie Croniche Intestinali, CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy.
Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome 00168, Italy.

Giovanni Camardese (G)

Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Rome 00168, Italy.

Classifications MeSH